跳至主要内容
临床试验/ISRCTN58752772
ISRCTN58752772进行中(未招募)未知

on-interventional study to investigate the effectiveness of emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A with and without FVIII inhibitors

Roche (Germany)0 个研究点目标入组 168 人开始时间: 2022年2月9日最近更新:

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
168

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
Male

入选标准

  • 1. Participants of any age with congenital severe haemophilia A with or without FVIII inhibitors
  • 2. Participants undergoing treatment with emicizumab according to Summary of Product Characteristics (SPC) (start of treatment with emicizumab maximum 3 months prior to study entry)
  • 3. Must sign informed consent by the legal representative or participant or both, as required
  • 4. Selection criteria for Cohort A include participants diagnosed with severe congenital haemophilia A (<1% FVIII activity) and no present FVIII inhibitor at the start of emicizumab treatment, patients who completed successful ITI before the start of Emicizumab treatment are eligible.
  • 5. Selection criteria for Cohort B include participants diagnosed with congenital haemophilia A (any severity) with FVIII inhibitor activity at the start of emicizumab treatment or ongoing ITI at the start of emicizumab treatment

排除标准

  • 1. Participants having bleeding disorder other than congenital haemophilia A
  • 2. Treatment with emicizumab outside of the SPC at study entry
  • 3. Any contraindication for treatment with emicizumab according to current SPC
  • 4. Current participation in an interventional study

研究者

发起方
Roche (Germany)

相似试验